Products
TYPICAL PATIENT TREATMENT DURATION & PROTOCOL
TYPICAL TREATMENT TIME FOR PATIENTS IS 3-7 DAYS
Adherence is best over areas of compromised epithelium.
The rate of breakdown and absorption is proportional to the surface area of compromised epithelium. Greater epithelial compromise means quicker breakdown and absorption. Mostly intact epithelium will take longer to break down and may not adhere optimally. Taking a wekcel and “drying” the cornea can create epithelial micro-defects which optimize adherence in cases where there isn’t much epithelial compromise to start with.
In cases with diffuse epithelial loss the graft may be absorbed in one day, with mostly intact epithelium the graft may still be visible at 7 days.
Using a bandage is part of the treatment process with Eclipse and Aurora. The two concerns when sleeping with a contact lens are around oxygen and the risk of infection.
Unless the patient is herpetic, it’s recommended to give the patient a combination antibiotic-steroid drop to keep the most common ocular surface bacterial offenders in check.
The steroid helps to offset hypoxic sequelae effectively for the duration of treatment. It’s also recommended to administer a nonpreserved lubricant drop to support the exchange of fluid and oxygen under the contact lens for the duration of treatment.
NO ADDITIVES OR PRESERVATIVES
NO ADDITIVES | NO PRESERVATIVES | NO ANTIBIOTICS
Available in Three Styles and Six Sizes to Fit Your Needs
Watch: The Many Benefits of Amnion Membrane
Revolutionizing Dry Eye Treatment: Ophthalogix Eclipse & Aurora Solutions
Are Aurora, Tetra and Eclipse Safe?
- Collection of the donor tissue is performed in an aseptic manner by appropriately licensed tissue establishments
- Placentas are recovered from planned C-sections which helps to minimize the potential for contamination during recovery
- Placental donors go through a rigorous pre-screening qualification
- Placental donors are tested to confirm they are free from disease
- No chemical cross-linking added during processing
- Processed in accordance with the safety guide- lines provided by the U.S. Food and Drug Administration (FDA) – Human Cellular and Tissue-based Products (HCT/P) (21 CFR Part 1271)
- Processed in accordance with the standards from the American Association of Tissue Banks (AATB)
What is Amnion?
Amnion is the placental tissue that surrounds and protects the fetus during development in utero. The properties of amnion that benefit the fetus also make it an effective material for providing barrier protection in a number of surgical settings. Repurposing this versatile tissue to improve surgical procedures is supported by studies in published literature which describe its successful and safe clinical use. Amnion consists primarily of fibrillar and membranous collagens, elastin, and a mix of growth factors and cytokines that provide the properties unique to placental tissues.
Amnion for Ophthalmology and Optometry
The scientific and peer reviewed literature describe a number of benefits from the clinical use of amnion tissues in ophthalmic procedures, including:
- Anti-inflammatory and anti-scarring effects and contain growth factors that promote epithelial wound healing on the surface of the eye [13]
- Band and bullous keratopathy [5]
- Chemical Burns of the ocular surface [6,7]
- Conjunctival defects and conjuctivochalasis [8,9]
- Pterygium [1]
- Corneal Transplant, trabeculectomy [10]
- Severe Corneal Ulcers [2,3,4,11]
- Stevens-Johnson Syndrome [12]
The versatile and powerful properties of amnion have been improving surgical outcomes for decades.
Amnion Reimbursement
2023 CODING & REIMBURSEMENT GUIDE FOR OPHTHALOGIX ECLIPSE & TETRA AMNIOTIC MEMBRANE
Ophthalogix is providing this summary of Medicare payment rates to share information on payments for items and services related to its products. Because Medicare rates are the only publicly posted rates, and many other payers use Medicare payment levels to set their own rates, the figures below are specified as a frame of reference for our customers.
While Ophthalogix is committed to provide accurate coding information, this information should not be interpreted as providing clinical advice, dictating reimbursement policy or substitute for the judgment of a practitioner. It is always the provider’s responsibility to determine and submit appropriate codes, charges and modifiers for rendered services.
Ophthalogix assumes no responsibility or liability for the timeliness, accuracy and completemeness of the information contained below. Since reimbursement laws, regulations and payor policies change frequently, it is recommended that providers consult with their payors, coding specialists, and/or legal counsel regarding coverage, coding and payment issues.
CPT CODE: 65778: Placement of amniotic membrane on the eye; without sutures
2022 NATIONAL MEDICARE PAYMENT RATE NON-FACILITY: $1,443